Shareholders Equity: The sum of preferred and common equity items.
Cartesian Therapeutics, Inc. (RNAC) had Shareholders Equity of $-2.53M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.30M |
|
$13.26M |
|
-- |
|
$0.30M |
|
$22.11M |
|
$-21.81M |
|
$37.70M |
|
$15.89M |
|
$15.89M |
|
$15.89M |
|
$15.89M |
|
$15.89M |
|
$15.89M |
|
$-21.81M |
|
$-21.22M |
|
25.98M |
|
26.45M |
|
$0.51 |
|
$0.50 |
|
| Balance Sheet Financials | |
$163.40M |
|
$12.29M |
|
$225.50M |
|
$388.89M |
|
$12.26M |
|
-- |
|
$379.16M |
|
$391.42M |
|
$-2.53M |
|
$-50.69M |
|
|
Shareholders Equity |
$-2.53M |
26.00M |
|
| Cash Flow Statement Financials | |
$-40.63M |
|
$-3.67M |
|
$-7.96M |
|
$214.28M |
|
$162.06M |
|
$-52.22M |
|
$5.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-7319.13% |
|
-7319.13% |
|
-- |
|
5330.87% |
|
4448.99% |
|
$-44.30M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.84 |
|
106.91 |
|
-628.65% |
|
-31.34% |
|
4.08% |
|
-628.65% |
|
$-0.10 |
|
$-1.68 |
|
$-1.54 |
|